There really are a bunch more, but I’d be getting into more technical stuff.
I’d just like to say, regardless of whether Dstock’s assumptions are right about Merck’s vaccine manufacturing expansion in part being connected to cancer vaccine prep; the more general takeaway is that BP is truly shifting to immunotherapy full speed ahead.
The recent article about Gardasil and Keytruda being mega-blockbusters is only the beginning, and that requires infrastructure preparation. BPs are no longer reluctant to make investments in that future.
Market Data 
Markets 
AI
